Richard F. Dunne MD

Gastrointestinal Cancer, Hematologic Oncology

Associate Professor of Medicine, Leader of the Gastrointestinal Cancer Unit and Clinical Research Program, Wilmot Cancer Institute, University of Rochester School of Medicine & Dentistry

Join to View Full Profile

601 Elmwood Ave# 704Rochester, NY 14642
Phone+1 585-275-5863
Fax+1 585-273-1051

Education & Training

University of Rochester School of Medicine and DentistryMasters in Clinical Investigation, Clinical Research, 2016 - 2019
University of RochesterPost-Doctoral Fellowship, 2016 - 2018
University of Rochester Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2015
University of Rochester Medical CenterChief Residency, Internal Medicine, 2012 - 2013
University of Rochester Medical CenterResidency, Internal Medicine, 2009 - 2012
State University of New York Downstate Medical Center College of MedicineClass of 2009

Certifications & Licensure

NY State Medical License 2012 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Cancer Grand Challenges: Cachexia-Understand and Reverse Cachexia NCI and CRUK
KL2 Mentored Career Development Award: Randomized Interventional Trial Investigating Dietary Supplementation and Exercise in Cancer Cachexia University of Rochester Clinical and Translational Science Institute, 2019-2021
NCI R25 Workshop in Supportive Care and Oncology Grantee Mass General Hospital, 2018
Department of Medicine Research Pilot Grand Award: Investigating Tumor Genomics in Pancreatic Cancer Cachexia University of Rochester Medical Center, 2017-2018
Wilmot Cancer Research Fellowship Award: Evaluating Exercise for Treatment of Cancer Cachexia Wilmot Foundation for Cancer Research, 2015-2018
Join now to see all

Clinical Trials

Induction Chemotherapy for Locally Advanced Esophageal Cancer Start of enrollment: 2017 Jun 19
ACTIVE_NOT_RECRUITING
PHASE2
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Start of enrollment: 2018 Aug 31
COMPLETED
PHASE1, PHASE2
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer Start of enrollment: 2019 May 03
ACTIVE_NOT_RECRUITING
PHASE2
Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia Start of enrollment: 2020 Apr 24
Completed
Phase 1
A Study to Evaluate the Safety and Tolerability of SX-682 in Combination with Nivolumab As a Maintenance Therapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma Start of enrollment: 2020 Nov 23
RECRUITING
PHASE1
The Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients With Cancers of the Gastrointestinal Tract With Pre- Cachexia or Cachexia Start of enrollment: 2016 Jun 29
Completed
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Neoadjuvant pemigatinib as a bridge to living donor liver transplantation for intrahepatic cholangiocarcinoma with FGFR2 gene rearrangement.
Matthew M Byrne, Richard F Dunne, Jennifer I Melaragno, Mariana Chávez-Villa, Aram Hezel
American Journal of Transplantation. 2025-03-01
Early identification of weight loss trajectories in advanced cancer and associations with survival.
Sophia Fuller, Stacey Alexeeff, Bette Caan, Marcus Dasilva Goncalves, Richard F Dunne
Journal of the National Cancer Institute. 2025-02-18
Prognostic implications of tumor histology and microenvironment in surgically resected intrahepatic cholangiocarcinoma: a single institutional experience.
Irene Y Chen, Richard F Dunne, Xiaoyan Liao
Virchows Archiv. 2025-02-01

Journal Articles

Germline Cancer Susceptibility Gene Variants, Somatic Second Hits, and Survival Outcomes in Patients with Resected Pancreatic Cancer
Richard F Dunne, Leona A Doyle, William C Hahn, Jason L Hornick, Andrea J Bullock, Sapna Syngal, Albert C Koong, Natalia Khalaf, Brian M Wolpin, Douglas A Rubinson, Da..., Nature

Lectures

Evaluating the effects of a structured exercise intervention on physical self-worth in men with prostate cancer: Addressing an unmet need.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

Earlier Identification of Cachexia in Advanced Cancer PossibleFebruary 18th, 2025
Will Ponsegromab Be a Game Changer for Cancer Cachexia?October 17th, 2024
New Cancer Cachexia Treatment Boosts Weight Gain and Patient ActivitySeptember 19th, 2024
Join now to see all

Grant Support

The Pancreatic Cancer Tumor Genome and its Influence on the Development of Cancer CachexiaUniversity of Rochester Department of Medicine2017–2018
Evaluating the Effects of a 12 week Home-based Exercise Intervention on Physical Performance in Patients with Cancers of the Gastrointestinal Tract with Pre-cachexia or Cachexia: A pilot study.Wilmot Foundation for Cancer Research2015–2018